Tu1845 COMPARATIVE EFFECTIVENESS OF SURVEILLANCE COLONOSCOPY TIMING ON COLORECTAL CANCER OUTCOMES (STAGE, TREATMENT, MORTALITY) IN A NATIONAL COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE

2020 ◽  
Vol 158 (6) ◽  
pp. S-1185
Author(s):  
Jason K. Hou ◽  
Hyunseok Kim ◽  
Ruben Hernaez ◽  
Shubhada Sansgiry ◽  
Akbar K. Waljee ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Comparative Effectiveness ◽  
Surveillance Colonoscopy ◽  
Cancer Outcomes ◽  
National Cohort ◽  
Inflammatory Bowel ◽  
Treatment Mortality

Surveillance in inflammatory bowel disease: an overview

2019 ◽  
Vol 17 (8) ◽  
pp. 32-37
Author(s):  
Sara Koo ◽  
Jignesh Jatania ◽  
Colin Rees
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Duration ◽  
The Other ◽  
Surveillance Colonoscopy ◽  
Targeted Biopsy ◽  
White Light Endoscopy ◽  
Increased Risk ◽  
Inflammatory Bowel

Patients with inflammatory bowel disease (IBD), including both ulcerative colitis and Crohn's disease, are at an increased risk of developing colorectal cancer. It is well accepted that this risk increases after 8–10 years of disease duration. Patients should be offered a surveillance colonoscopy after this time. Previously, white-light endoscopy with random biopsies every 10 cm was undertaken for surveillance, but recent evidence suggests that chromoendoscopy along with targeted biopsy is superior to this and the other available methods. This article reviews the available evidence for IBD surveillance, surveillance guidelines and the evidence for chromoendoscopy. Additionally, an overview of the assessment, reporting of any visible abnormal lesions and management of subsequently proven dysplastic lesions is given.

Sign in / Sign up

Export Citation Format

Share Document